Bisolex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bisolex

Quick Facts

Property Description
Active ingredient Bromhexine hydrochloride
Form Tablet, oral solution, syrup
Pharmacological class Mucolytic and secretolytic agent
Common use Easing productive cough and clearing mucus
Origin Synthetic derivative of vasicine

What Type of Medicine is Bisolex?

Bisolex is a single-component pharmaceutical preparation defined as a mucolytic agent and secretolytic agent. It is classified within the pharmacological group of mucoactive agents dedicated to regulating bronchial secretions and managing issues associated with abnormal or thickened respiratory mucus.

The core identity of this medication rests on its active substance, Bromhexine hydrochloride (INN), a compound known for its systemic action on the respiratory epithelium. Bromhexine is categorized as both a mucolytic and an expectorant. This dual designation indicates that the drug is chemically designed to facilitate the clearance of mucus from the respiratory tract. Bromhexine is a synthetic compound derived from the naturally occurring alkaloid vasicine, ensuring a standardized action across its various systemic applications.

Composition and Available Forms of Bisolex

The primary substance in Bisolex is Bromhexine hydrochloride, delivered in forms suitable for oral administration. Unlike some similar formulations, Bisolex is typically offered in multiple strengths and forms, including a readily administered syrup or oral solution in addition to the tablet, making it adaptable for various patient groups.

As a single-component product, its high-level composition focuses exclusively on the active Bromhexine hydrochloride combined with basic pharmaceutical excipients. Bromhexine's action involves enhancing hydrolysis of acid mucopolysaccharide polymers and increasing serous mucus production in the respiratory tract. This mechanism is what differentiates Bisolex from simple antitussive agents that merely suppress the cough reflex.

General Purpose and Therapeutic Benefit

The general purpose of Bisolex is to support and facilitate the efficient removal of thick or excessive mucus from the respiratory airways, addressing the discomfort associated with a productive cough. A typical, neutral use scenario involves managing conditions where the buildup of thick secretions impedes normal breathing and cough function.

The medicine achieves this by transforming the viscous, sticky phlegm into a looser, more fluid substance. This change in consistency supports enhanced mucociliary clearance, making the natural process of coughing significantly more effective in clearing the airways and relieving the sensation of phlegm retention.

Regulatory References

  1. US National Library of Medicine

What side effects are possible with Bisolex?

Possible Side Effects and Safety Information

The safety profile of Bisolex (bromhexine hydrochloride) is classified by regulatory authorities based on system-organ classes and observed frequencies in clinical use. The following adverse reactions and safety statements are officially documented in government-approved prescribing information.


Classification of Officially Documented Adverse Reactions

The most frequently reported adverse effects are typically gastrointestinal. The classification below is consistent with regulatory standards for communicating risk.

Frequency Category System-Organ Class (SOC) Officially Listed Adverse Reactions
Uncommon Gastrointestinal disorders Nausea, vomiting, diarrhea, abdominal pain
Rare Skin and subcutaneous tissue disorders Rash, urticaria
Not known Immune system disorders Anaphylactic reactions, including anaphylactic shock, angioedema
Skin and subcutaneous tissue disorders Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

High-Level Safety Considerations

Official documentation notes the potential for Serious Cutaneous Adverse Reactions (SCARs) and anaphylactic reactions, which are considered rare but clinically significant. These events involve the skin and the immune system.

Population-Specific Constraints: Regulatory safety information advises particular caution for individuals with a history of peptic ulcer disease due to the potential for mild gastric irritation. Caution is also specified for patients with severe hepatic impairment, where the drug's metabolism may be altered.

A functional safety note is included regarding the potential for Bisolex to cause an increased concentration of certain antibiotics in the respiratory secretions when used simultaneously.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Bisolex (Bromhexine hydrochloride) confirms that no specific overdose symptoms unique to the compound have been formally reported in humans. Manifestations observed in instances of exposure beyond labeled use are generally consistent with an exaggeration of the medicine's known adverse effects.

Documented Overdose Presentations

The most commonly noted clinical signs align with effects on the gastrointestinal system, presenting as nausea, vomiting, diarrhea, and upper abdominal pain. Other signs consistent with increased exposure include headache and dizziness. Furthermore, a transient rise in serum aminotransferase values has been documented in certain cases. The official profile notes a potential for an undesirable increase in the volume of bronchial secretions.

Required Emergency Actions

In the event of a suspected or confirmed overdose exposure, official labeling mandates that individuals seek immediate medical attention. This includes the explicit instruction to immediately contact a doctor, pharmacist, or the national Poisons Information Centre for advice. These actions are required even if the individual appears to be asymptomatic.

Management and Antidote Information

Management of Bisolex overdose is defined in regulatory documents as symptomatic and supportive treatment determined by the patient's clinical state. It is officially documented that no specific antidote is known for Bromhexine hydrochloride overdose.

Therapeutic Uses of Bisolex

What Bisolex Treats: Main Uses and Benefits

Bisolex is primarily used to provide supportive symptomatic relief for conditions of the respiratory tract characterized by the production of viscid (thick) and excessive mucus. Its therapeutic benefit is centered on easing the discomfort and strain caused by difficult-to-expel phlegm.

Bromhexine hydrochloride is categorized as a mucolytic. The medication is commonly used when short-term symptomatic assistance is needed in conditions like acute bronchitis, influenza, and the common cold, and is applied for managing symptoms during exacerbations of chronic bronchitis and certain presentations of COPD (Chronic Obstructive Pulmonary Disease). The primary therapeutic purpose is relevant for easing symptoms related to the abnormal consistency of secretions. This supports easier expectoration and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Viscid Mucus

  • Bisolex is commonly used to help manage the symptoms of a productive cough complicated by thick or excessive secretions.
  • Its use assists with maintaining functional stability when symptoms are more noticeable, offering supportive relief to adults and children with acute or chronic mucus disorders.
  • The medication may contribute to easing the discomfort associated with chest congestion, which is relevant for managing symptoms that interfere with daily comfort.

Regulatory References

  1. Australian Therapeutic Goods Administration Monograph

Eligibility and Restrictions for Use

Eligibility Scope

Classification Status/Rules (Per Regulatory Labeling)
Populations Contraindicated Must Not Use if known hypersensitivity to bromhexine hydrochloride or any formulation excipients [3.1].
Populations Allowed Adults and adolescents over 12 years of age are generally approved for use [3.4].
Pediatric Use Use is approved for children mathbf2 years and older [3.4]. Use is not recommended for children younger than mathbf2 years of age [2.4].
Reproductive Status Pregnancy and lactation use is not recommended [3.3]. The substance is excreted in breast milk, and use should be avoided during the first trimester of pregnancy [3.1].

Eligibility-Related Restrictions

Official documents mandate that Bisolex must be used with caution in several populations. This conditional use is required for patients with a documented history of peptic or gastric ulceration [3.1].

Organ Impairment: Caution is also required in individuals with severe hepatic impairment (liver disease) or severe renal impairment (kidney failure) [3.1]. This restriction is based on the potential for reduced clearance of bromhexine or its metabolites in these conditions [3.4]. Some formulations may be restricted in patients with rare hereditary problems like fructose intolerance if they contain specific excipients [3.3].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Bisolex (Bromhexine hydrochloride) establishes that there are no clinically relevant unfavourable interactions reported with co-administered medications such as ampicillin, amoxicillin, oxytetracycline, or erythromycin. Formal regulatory assessments also indicate that metabolic changes, such as those related to specific CYP 450 enzymes, are considered unlikely, and the metabolic pattern is not substantially hinted to be changed by substances like sulphonamide.

A key documented pharmacodynamic interaction involves co-administration with certain antibiotics. Regulatory sources state that, following the administration of Bromhexine, the concentrations of antibiotics, specifically amoxicillin, erythromycin, and oxytetracycline, are increased in the sputum and bronchopulmonary secretions.

Regarding systemic exposure, a pharmacokinetic modification is documented with external factors: Concomitant food intake leads to an increase in the resulting Bromhexine plasma concentrations. No mandatory timing rules for separating administration from other drugs, nor any formal drug-drug contraindicated combinations, are specified in the reviewed product information.

A population-specific note is included regarding drug clearance: the clearance of Bromhexine or its metabolites may be reduced in patients with severe hepatic impairment or severe renal impairment.

Mechanism of Action

Bisolex (Bromhexine hydrochloride) exerts its action through a dual-mechanism focused on the physicochemical properties and transport of respiratory secretions. The primary action is mucolytic, involving the modulation of lysosomal enzymes within mucus-secreting cells. This enzymatic enhancement drives the hydrolysis and depolymerization of long-chain acid mucopolysaccharide polymers and mucoprotein fibers. This molecular breakdown alters the material state of the secretions.

Simultaneously, the drug acts as a secretolytic agent by stimulating the serous glands of the respiratory epithelium to increase the output of watery fluid. This sequence results in a reduction of secretion viscosity and elasticity. Furthermore, the mechanism includes a secretomotoric effect on the ciliated epithelium, increasing the rate and coordination of ciliary beating. The resultant decrease in mucus viscosity, coupled with the acceleration of ciliary movement, contributes to enhanced mucociliary clearance.

Dosage and Administration Information

Bisolex, which contains the active ingredient Bromhexine hydrochloride, is indicated for oral administration only. The medication is used to facilitate the clearance of thick, excessive mucus. It is available in several forms, including tablets and oral solutions or syrups, with administration permitted with or without food.

Accurate measurement is a key procedural step for proper use; for liquid forms, a calibrated measuring device must be used, and any soluble tablets must be allowed to fully dissolve in water prior to intake.

The standard administration schedule involves a specific dose and frequency tailored by age group:

Population Standard Dosing Regimen Frequency
Adults (≥ 12 years) 8 mg per single dose. Maximum dose up to 48 mg daily. Three times daily (t.i.d.)
Children (6-11 years) 8 mg per single dose. Three times daily (t.i.d.)
Children (2-5 years) 4 mg per single dose. Twice daily (b.i.d.)

This regimen is intended for short-term symptomatic use. If the underlying condition persists or shows no improvement after four to five days of use, medical review should be sought, as the continued necessity for the medication must be assessed.

Recent Clinical Evidence

Bisolex: Recent Clinical Evidence

Clinical research involving Bisolex (Bromhexine) has primarily focused on its secretolytic action in respiratory conditions characterized by increased and viscous mucus production. The body of evidence consists of randomized controlled trials (RCTs), open-label studies, and systematic reviews investigating its use.

Evaluation in Bronchopulmonary Disorders

Studies examined whether Bisolex was associated with changes in mucus properties and overall airway clearance. In multiple controlled trials, participants receiving the drug were reported to have a decrease in mucus viscosity compared to those in the placebo group. The primary focus of these investigations was on objective measures of sputum rheology and lung function markers.

A systematic review summarizing data across several RCTs reported that the drug's use was associated with an improvement in the objective measure of sputum volume and expectoration in patients with certain acute and chronic bronchopulmonary disorders. The observed effects were generally within the context of supportive care.

Safety Profile and Research Limitations

The safety profile observed in clinical trials indicates that the drug is generally tolerated, with the most frequently reported adverse events being mild gastrointestinal disturbances. Serious adverse events were reported rarely.

Research has not definitively established the long-term effects or the safety profile for all patient populations, including those with severe renal or hepatic impairment. Further investigation is needed to fully assess the drug’s role in managing specific long-term respiratory outcomes and its comparative performance against all other treatment options.

Key Studies & References

  1. Guideline for the Management of Cough in Adults and Children (focusing on non-specific cough and self-care agents)

Frequently Asked Questions (FAQ)

Common questions about Bisolex (FAQ)

Q: Is Bisolex the same thing as the ingredients in other common medicines?

The active ingredient in this medicine is Bromhexine hydrochloride. This compound is known as an International Nonproprietary Name (INN) and is the same active substance used in the formulation of many different medicinal products worldwide.


Q: Are there any common foods or drinks that interact with Bisolex?

Official documentation indicates that concomitant food intake can lead to an increase in the plasma concentration of the active ingredient. However, regulatory sources have not specified mandatory timing rules for administration relative to meals. No specific warnings regarding common non-alcoholic drinks are documented.


Q: Can elderly patients take Bisolex?

Official product information notes that there are no specific data regarding the pharmacokinetics (how the medicine moves through the body) of the active ingredient in elderly patients. Regulatory documentation does not mandate a specific dose adjustment or restriction solely based on advanced age.


Q: Why is it important to know who cannot use Bisolex?

This information is legally defined to outline the risks associated with use, highlighting the potential for serious adverse reactions, such as anaphylaxis and severe cutaneous reactions. It also sets boundaries for use in individuals with pre-existing conditions like peptic ulceration or severe organ impairment.


Q: Is there a generic version of Bisolex available?

The name of the active substance in Bisolex is Bromhexine hydrochloride. As the INN, this compound may be available as a generic medicine in various markets, in addition to being sold under brand names like Bisolex.


Q: What is the role of regulatory agencies in approving Bisolex?

Regulatory agencies, such as the EMA and TGA, play a primary role in authorizing the medicine. They review clinical studies and safety data to approve the medication's intended use and establish standardized dosing schedules and safety warnings. They also continually monitor for post-market adverse events.


Q: How do doctors monitor the effectiveness of Bisolex?

Product information states that the necessity for the medication must be assessed if the condition persists or shows no improvement after four to five days of use. Clinical studies typically assess the medicine’s effects using objective measures, such as the viscosity (thickness) and volume of sputum.


Q: Does Bisolex work immediately after I start taking it?

Studies report that the active ingredient is rapidly and extensively absorbed in the intestine following oral administration. Increased concentrations of the active ingredient in lung tissue have been observed within two hours of taking the medicine.


Q: How long does the effect of Bisolex last in my system?

According to official pharmacokinetic data, the elimination half-life of the active ingredient in plasma is reported to be approximately 12 hours. The half-life refers to the time it takes for half of the medicine to be cleared from the bloodstream.


Q: Is Bisolex safe to use if I have high blood pressure?

Official product information for the single-component medication does not list high blood pressure, or hypertension, as a specific caution or contraindication. Restrictions are generally confined to populations where metabolism or clearance may be affected.


Q: What happens if I forget to take a dose of Bisolex?

Guidance provided in the Patient Information Leaflet (PIL) states that if a dose is forgotten, it can be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. Regulatory guidance states that a double dose must not be used to compensate for a missed one.


Q: Does Bisolex have a risk of dependence or addiction?

Regulatory reviews establish the safety profile for the medicine. The official product information and safety data do not list dependence, addiction, or abuse potential as concerns for this medicine.


Q: Is Bisolex known to interact with birth control pills?

Official product information does not document any known drug interaction between the active ingredient and oral contraceptive medicines. The regulatory profile focuses on interactions that have a confirmed clinical relevance.


Q: What is the purpose of the inactive ingredients in Bisolex?

Inactive ingredients, known as excipients, are included for manufacturing purposes, such as formulation stability, consistency, and taste. For example, some liquid formulations use maltitol liquid, which means the product is often considered acceptable for use by individuals with diabetes, though the excipient may also have a mild laxative effect.


Q: Does Bisolex affect blood sugar levels?

Some liquid formulations of this medication are specified as sugar-free in the official product information. This designation means the product does not contain added sugar, making it an option for individuals with diabetes.


Q: Does Bisolex require a prescription?

The legal status of Bisolex is determined by local regulatory authorities and can vary by country. In some regions, the product is available as a non-prescription medicine, while in others, it may require a prescription.


Q: Can Bisolex interfere with driving or operating machinery?

The official safety profile is reviewed to determine the need for driving warnings. Regulatory documents do not include specific warnings that the medicine commonly interferes with the ability to drive or use heavy machinery.


Q: Is Bisolex safe to take with common pain relievers?

Official product information does not list any known drug interaction between the active ingredient and common over-the-counter pain relievers, such as ibuprofen or paracetamol. The regulatory profile is focused on clinically relevant interactions.


Q: Are there any specific tests needed before starting Bisolex?

Official product information does not mandate any specific laboratory tests or clinical screening prior to starting the medicine. Cautions are only highlighted for patients with a known history of conditions like severe liver or kidney impairment.


Q: Are there official warnings about combining Bisolex with alcohol?

Regulatory documents do not contain any specific warnings or interactions regarding the combination of the active ingredient and alcohol. This is based on the safety and interaction data submitted to the regulatory authorities.

How should Bisolex be stored and disposed of?

The storage and disposal of Bisolex (Bromhexine hydrochloride) must adhere strictly to the conditions documented in the official regulatory labeling.

Storage Requirements

Scope Element Official Regulatory Requirement
Temperature: Store below 25 C or 30 C (controlled room temperature).
Protection: Protect from light and moisture; keep container tightly closed.
Handling: Do not freeze the medicine; keep in the original container.
Child Safety: Keep out of the sight and reach of children.

Disposal Requirements

Official instructions require the safe disposal of all unused or expired Bisolex according to local pharmaceutical waste regulations. The medicine should not be disposed of via household wastewater or general trash. Consumers are directed to utilize authorized medicine take-back programs or collection points where they are available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bisolex found in:

A-Z Index: